Coley's Toxins: The Pioneering Foundation of Cancer Immunotherapy

Coley's Toxins, developed in the late 19th century by the American bone surgeon Dr. William B. Coley, represents the first systematic attempt to harness the immune system to fight cancer. This essay explores the fascinating history of this treatment, its initial clinical successes, the scientific and political reasons for its decline, and the modern molecular understanding that has vindicated Coley's instincts and established him as the "Father of Cancer Immunotherapy." The story of Coley's Toxins is not merely a historical footnote but a foundational chapter in the development of modern oncology, offering profound lessons about the relationship between infection, inflammation, and malignancy.

---

1. Introduction: The Surgeon Who Pursued a Hunch

William Bradley Coley was born on January 12, 1862, in Saugatuck, Connecticut, into an old New England family . He received his bachelor's degree in Classics from Yale University before pursuing medicine at Harvard Medical School, where he earned his medical degree in 1888 . After graduation, Coley began his surgical internship at New York Hospital, now part of Weill Cornell Medical Center, embarking on what would become an illustrious career as a bone surgeon at the New York Cancer Hospital, the forerunner of Memorial Sloan Kettering Cancer Center .

In 1890, during his first year of private practice, Coley encountered a case that would alter the trajectory of his career and, ultimately, the history of oncology. A 17-year-old patient named Elizabeth "Bessie" Dashiell presented with a painful swelling in her hand following a minor injury . Coley soon discovered the mass to be an aggressive bone sarcoma. The standard of care at the time was radical amputation, which Coley performed. Despite this drastic intervention, Bessie died just ten weeks later from widespread metastasis .

Deeply distressed by the death of one of his first patients, Coley resolved to find better methods. He retreated to the hospital's medical archives, reviewing records of similar sarcoma cases in search of any clue that might suggest an alternative approach . There he found a case that seemed miraculous: a patient named Fred Stein, a German immigrant with an inoperable round cell sarcoma of the neck, whose tumor had completely and inexplicably vanished after he developed a severe skin infection called erysipelas . The hospital's physicians had documented the case with astonishment, noting that Stein had been discharged with no trace of cancer. Coley, determined to understand this phenomenon, tracked Stein down in Manhattan and confirmed that he remained cancer-free years later .

This discovery ignited Coley's lifelong pursuit. He hypothesized that the bacterial infection had somehow provoked the patient's body to fight and destroy the tumor. Over the next four decades, Coley would systematically test this hypothesis, injecting over one thousand cancer patients with bacterial products and documenting his results in more than 150 scientific papers .

2. The Formulation: From Live Bacteria to Standardized Toxins

Coley's initial experiments were audacious by any standard. In 1891, he treated his first patient, an Italian immigrant named Zola, who had a life-threatening tumor described as "the size of a small hen's egg" in his right tonsil . Reasoning that he needed to replicate the erysipelas infection that had cured Fred Stein, Coley injected live Streptococcus pyogenes bacteria directly into Zola's tumor. After several injections over five months, Zola finally developed a full-blown erysipelas infection, and as Coley had hoped, the tumor began to dissolve. Within two weeks, it had disappeared entirely, and Zola survived for another eight years before succumbing to a recurrence .

Over the next two years, Coley treated ten more patients with live Streptococcus cultures. While some responded, the approach proved dangerously unpredictable. Live infections were difficult to control, and two of Coley's patients died from the very infections he had induced . Recognizing the unacceptable risk, Coley modified his approach. He began using bacteria that had been heat-killed and filtered, eliminating their ability to cause progressive infection while, he hoped, retaining their tumor-fighting properties .

By 1893, Coley had settled on a formulation that would become known as "Coley's Toxins": a mixture of heat-killed Streptococcus pyogenes (the erysipelas-causing organism originally identified by German surgeon Friedrich Fehleisen in 1883) and Serratia marcescens (then known as Bacillus prodigiosus) . The combination was based on empirical observations that mixed preparations seemed more potent, though the mechanism remained entirely unknown. Beginning in 1899, the formula was commercialized by Parke-Davis, America's oldest and largest drug manufacturer at the time, and it was widely used for the next thirty years by physicians around the world, including the famous Mayo brothers at the Mayo Clinic .

3. The Clinical Evidence: A Retrospective Reappraisal

Assessing the true efficacy of Coley's Toxins has been complicated by the historical nature of the evidence. Coley practiced in an era before modern clinical trial design, informed consent, or standardized response criteria. His patients often received the toxins in conjunction with surgery or other treatments, making it difficult to isolate the effect of the toxins alone .

Nevertheless, the volume of cases is substantial. Coley personally treated more than one thousand patients, and his daughter, Helen Coley Nauts, devoted her life to systematically compiling and analyzing her father's records and those of other physicians who used the toxins . In 1953, she founded the Cancer Research Institute specifically to advocate for the study of cancer immunotherapy and to preserve her father's legacy .

The most rigorous modern analysis of this historical data was published in 1999 by Richardson and colleagues . Using a retrospective cohort design with external controls, the researchers compared the survival of 128 patients treated with surgery and Coley's Toxins in New York between 1890 and 1960 against 1,675 controls from the Surveillance Epidemiology End Result (SEER) cancer registry who received a cancer diagnosis in 1983 . The groups were matched for age, sex, ethnicity, cancer site, stage, and treatment status. The Cox proportional hazards model, controlling for stage and menopausal status where applicable, revealed that the risk of death within ten years was not significantly different between the Coley patients and the 1983 SEER population for renal, ovarian, breast cancer, and soft-tissue sarcomas . This finding suggests that patients treated with surgery and Coley's Toxins in the pre-radiation era experienced survival rates comparable to those achieved with conventional non-radiotherapeutic approaches nearly a century later.

While the study's authors acknowledged significant limitations including small sample sizes, the potential inaccuracy of staging technology during Coley's era, and possible selection bias, the conclusion is striking: a treatment developed in the 1890s produced survival outcomes comparable to those of the 1980s for several cancer types .

4. The Decline: Why Was Coley's Work Abandoned?

Given these apparently impressive results, one might wonder why Coley's Toxins fell into disuse. The answer is multifactorial, involving scientific, technological, political, and regulatory dimensions.

The Rise of Radiation Therapy

The most immediate factor was the emergence of radiation therapy. Wilhelm Röntgen discovered X-rays in 1895, and by 1896 they were already being used therapeutically . Radium's therapeutic potential was recognized shortly thereafter. Unlike Coley's Toxins, which required careful titration to each patient and produced unpredictable fevers, radiation offered immediate, visible tumor destruction with consistent results across patients . The contrast could not have been starker: Coley's method was labor-intensive, time-consuming, and expensive, requiring individualized preparation and administration, while radiation could be delivered in a standardized fashion .

Institutional Politics and Powerful Opponents

Coley's position at Memorial Hospital was complicated by the presence of Dr. James Ewing, the most famous cancer pathologist in the country and the director of the hospital . Ewing was a passionate advocate for radiation therapy and, effectively Coley's boss, he championed its use for virtually all cancer patients . Ewing found Coley's vaccine method dangerous and unpredictable in patients already weakened by cancer . The conflict was exacerbated by a large financial gift from mining industrialist James Douglas, a radium advocate, which allowed Memorial to amass nearly eight grams of radium by the late 1920s, earning it the nickname "radium hospital" . Coley, though he had arranged for a wealthy friend to purchase two X-ray machines for the hospital and believed radiation had utility, came to view its effects as localized, temporary, and non-curative in the untrained hands of experimenters. The scientific majority disagreed .

The advent of chemotherapy in the 1940s pushed Coley's Toxins further to the margins. Another powerful figure at Memorial, Cornelius Rhoads, who had headed research for the Chemical Warfare Division during World War II, took a predictably military approach to combating cancer . Rhoads oversaw massive screening programs for chemical agents and was dismissive of approaches that did not share his faith in chemotherapy. In 1955, he ordered the manufacturing of Coley's Toxins at Memorial stopped, even while patients were still being treated with the therapy .

Regulatory Action

The final blow came with the Kefauver Harris Amendment to the Federal Food, Drug, and Cosmetic Act in 1962 . Passed in the wake of the thalidomide tragedy, the amendment required drug manufacturers to provide proof of safety and efficacy before FDA approval. While it contained a grandfather clause for long-used drugs like aspirin, the FDA in 1963 declared Coley's Toxins a "new drug," despite more than sixty years of clinical use, effectively banning its interstate sale without rigorous clinical testing . In 1965, the American Cancer Society added Coley's Toxins to its list of "Unproven Methods of Cancer Therapy," a designation that, though intended to protect patients from charlatans, effectively marked the therapy as beyond the pale for mainstream researchers .

5. Modern Mechanisms: Unraveling the Molecular Basis

For decades, Coley's work was dismissed or forgotten because no one could explain how it worked. The past twenty-five years have witnessed an explosion in understanding that has not only vindicated Coley but has placed his observations at the foundation of modern cancer immunology.

The Innate Immune System and Toll-like Receptors

The key breakthrough came with the discovery of Toll-like receptors (TLRs), for which the 2011 Nobel Prize in Physiology or Medicine was awarded. TLRs are pattern recognition receptors expressed on cells of the innate immune system that recognize conserved molecular structures found on pathogens, known as pathogen-associated molecular patterns (PAMPs) . When a TLR binds its cognate PAMP, it triggers a signaling cascade that activates the immune cell, leading to the production of inflammatory cytokines and the initiation of an adaptive immune response .

The Active Components: Cardiolipins and Polysaccharides

Recent research has begun to identify the specific molecules in Coley's Toxins responsible for immune activation. A 2023 study published in the Journal of the American Chemical Society systematically deconstructed Streptococcus pyogenes to identify its immunogenic components . Using a cell-based immune assay measuring TNF-α induction from murine bone-marrow-derived dendritic cells, researchers isolated a single active compound: a cardiolipin, specifically an 18:1/18:0/18:1/18:0 cardiolipin, which they named SpCL-1 . Cardiolipins are phospholipids found in bacterial and mitochondrial membranes. Synthetic SpCL-1 was shown to be a potent agonist of the TLR2-TLR1 heterodimer, with an EC50 of approximately 6 μM, and it robustly induced the pro-inflammatory cytokines TNF-α, IL-6, IL-23, and IL-12p40 . A synthetic analog with switched acyl chains had no activity, demonstrating a remarkably restricted structure-activity relationship . This work reveals that a single molecular species from S. pyogenes can reproduce at least part of Coley's observed immune activation.

Concurrent research has focused on the second component, Serratia marcescens. A 2025 study published in Glycobiology identified a 250 kDa polysaccharide, designated PS1, secreted by S. marcescens into its culture medium . When injected intravenously into mice bearing subcutaneous colon tumors at a dose of just 32 μg/kg, PS1 induced tumor-specific capillary hemorrhage in 90 percent of tumors within four hours . This effect was compared to CM101, a similar tumor hemorrhagic polysaccharide from Streptococcus agalactiae that had previously been safety tested in a Phase I clinical trial. The researchers propose that these polysaccharides represent the active principal ingredients of Coley's Toxins responsible for their tumor-destructive effects .

Neutrophil Reprogramming

A 2024 study in EMBO Molecular Medicine explored another mechanism by which bacterial products might exert anti-tumor effects . The researchers demonstrated that neutrophils trained with super-low dose endotoxin, a component of bacterial cell walls, adopt a potent immune-enhancing phenotype characterized by CD177loCD11bloCD80hiCD40hiDectin2hi expression. These reprogrammed neutrophils exhibited relieved suppression of adaptive T cells compared to untrained neutrophils. When transfused into tumor-bearing mice, they potently reduced tumor burden. Mechanistically, super-low dose endotoxin enabled the generation of these immune-enhancing neutrophils by activating STAT5 and reducing the innate suppressor IRAK-M . This work begins to clarify the long-held mystery of how "Coley's toxin" rejuvenates anti-tumor immune defense at the cellular level.

CpG DNA and TLR9

Another line of research has connected Coley's Toxins to the recognition of bacterial DNA. Unmethylated CpG oligodeoxynucleotide motifs, which are common in bacterial DNA but rare in vertebrate DNA, are recognized by TLR9 and display potent immune stimulatory properties . A 2003 NIH grant proposal explicitly framed the connection, noting that CpG ODN "could potentially link the pioneering work of Dr. William Coley's toxins to modern day cancer immunotherapy" . The proposal envisioned a vaccine strategy combining CpG ODN with irradiated tumor cells expressing GM-CSF to amplify anti-tumor immunity .

6. The Legacy: Coley's Vindication and Modern Immunotherapy

Coley's daughter, Helen Coley Nauts, devoted her life to preserving and advocating for her father's work. Through her efforts, and those of scientists like Lloyd Old, who served as the Cancer Research Institute's medical director from 1971 to 2011, the scientific establishment gradually came to reconsider Coley's contributions . Old famously wrote, "Those who have scrutinized Coley's results have little doubt that these bacterial toxins were highly effective in some cases" .

In 2007, the Cancer Research Institute funded a Phase I clinical trial of Coley's Toxins at Krankenhaus Nordwest hospital in Frankfurt, Germany, under the direction of Dr. Elke Jäger . This trial was unique in that it used toxins manufactured according to Good Clinical Practice guidelines with standardized bacterial components, and it incorporated modern laboratory measures of immune responses. While the primary objective was safety, one patient with metastatic bladder cancer experienced a 50 percent reduction in tumor burden that correlated with elevated cytokine levels, providing a tantalizing glimpse of modern-era efficacy .

Today, Coley is universally recognized as the "Father of Cancer Immunotherapy" . His fundamental insight that the immune system could be mobilized to fight cancer underlies the entire field of modern cancer immunology. Checkpoint inhibitors, which release the immune system's brakes; CAR-T cell therapy, which reprograms a patient's own T cells to recognize cancer; and cancer vaccines, which train the immune system to target tumor antigens, all trace their conceptual lineage back to Coley's audacious decision to inject bacteria into a dying patient's tumor .

7. Conclusion

The story of Coley's Toxins is one of the most remarkable in the history of medicine. A treatment developed in the 1890s based on a single case report, administered through trial and error, and ultimately abandoned in favor of more consistent and technologically sophisticated approaches, has proven to be conceptually prescient. The molecular mechanisms that Coley could not possibly have known are now being elucidated at the highest level of scientific rigor: specific cardiolipins activating TLR2-TLR1 signaling, polysaccharides inducing tumor-specific vascular disruption, bacterial DNA triggering TLR9 responses, and endotoxin reprogramming neutrophils for enhanced anti-tumor activity.

Coley's Toxins were never perfect. Their effects were inconsistent, their preparation variable, and their side effects significant. But they worked often enough, and in enough patients, to demonstrate a fundamental principle: the immune system, properly stimulated, can recognize and destroy cancer. That principle now underpins a multi-billion dollar industry and has saved countless lives.

The obstacles that led to the toxins' decline—the rise of radiation and chemotherapy, institutional politics, regulatory requirements, and the inability to explain mechanism—are also instructive. They remind us that promising therapies can be lost not because they are ineffective but because they are inconvenient, unprofitable, or misunderstood. They also remind us that scientific progress is not always linear; sometimes the future lies in revisiting and reinterpreting the past.

William Coley died on April 16, 1936, at the age of 74, at the Hospital for the Ruptured and Crippled in New York City . He did not live to see his vindication, but his daughter and the organization she founded ensured that his legacy would endure. Today, when oncologists speak of harnessing the immune system to fight cancer, they speak a language that Coley introduced more than a century ago. He was, indeed, ahead of his time.

8. Key Published Works and Resources

Primary Historical Sources: The collected monographs of Helen Coley Nauts, housed at the Cancer Research Institute and documenting over one thousand cases of Coley's Toxins treatment.

Modern Mechanistic Studies:

· 2023 Study: "Revisiting Coley's Toxins: Immunogenic Cardiolipins from Streptococcus pyogenes," Journal of the American Chemical Society

· 2025 Study: "Tumor Hemorrhage-inducing polysaccharides secreted by streptococci and Serratia," Glycobiology

· 2024 Study: "Reprogramming of immune-enhancing neutrophils by super-low dose endotoxin," EMBO Molecular Medicine

Clinical Retrospective:

· Richardson MA, et al. (1999). "Coley toxins immunotherapy: a retrospective review." Alternative Therapies in Health and Medicine

Organizations:

· Cancer Research Institute (founded 1953 by Helen Coley Nauts)

· American Association for Cancer Research (AACR) William B. Coley Award